Methotrexate

Methotrexate is immune. The oral administration of a relatively low dose, effective and non-toxic in other autoimmune diseases such as rheumatoid arthritis and psoriasis. The first test showed in the treatment of MS some decline in the frequency of relapses, but no benefit in patients suffering from Multiple Sclerosis gradual.

In a recent study, 60 ambulatory patients with progressive MS, and moderate or severe disability in the methotrexate 7.5 mg per week or placebo for two years. In the group that received treatment, significantly reduced the damage in the composite endpoint (EDSS arm evaluation function), it was noted the maximum benefit of the study early.

However, this is not important treatment effect when analyzed according to the traditional endpoint and EDSS. The impact of the disease on MRI activity also marginal. This was well tolerated low-dose methotrexate and no patient treatment stalled because of adverse events. Can it be treated for long periods with methotrexate cause irritation of the mucous membranes, and gastrointestinal symptoms, liver, and pulmonary fibrosis, and myelosuppression.